X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs SANOFI INDIA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH SANOFI INDIA STERLING BIOTECH/
SANOFI INDIA
 
P/E (TTM) x -0.3 40.4 - View Chart
P/BV x 0.0 8.7 0.2% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 STERLING BIOTECH   SANOFI INDIA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
SANOFI INDIA
Dec-16
STERLING BIOTECH/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs114,560 0.2%   
Low Rs34,400 0.1%   
Sales per share (Unadj.) Rs26.81,028.5 2.6%  
Earnings per share (Unadj.) Rs-15.0129.0 -11.6%  
Cash flow per share (Unadj.) Rs-5.5186.0 -2.9%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs54.9753.6 7.3%  
Shares outstanding (eoy) m267.8723.03 1,163.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.4 6.0%   
Avg P/E ratio x-0.534.7 -1.3%  
P/CF ratio (eoy) x-1.324.1 -5.3%  
Price / Book Value ratio x0.15.9 2.1%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m1,862103,174 1.8%   
No. of employees `0001.43.6 37.4%   
Total wages/salary Rs m5473,592 15.2%   
Avg. sales/employee Rs Th5,303.36,537.7 81.1%   
Avg. wages/employee Rs Th403.8991.4 40.7%   
Avg. net profit/employee Rs Th-2,959.0819.8 -361.0%   
INCOME DATA
Net Sales Rs m7,18123,686 30.3%  
Other income Rs m43708 6.0%   
Total revenues Rs m7,22324,394 29.6%   
Gross profit Rs m9475,281 17.9%  
Depreciation Rs m2,5431,313 193.7%   
Interest Rs m4,37715 29,180.7%   
Profit before tax Rs m-5,9314,661 -127.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9241,691 -113.8%   
Profit after tax Rs m-4,0072,970 -134.9%  
Gross profit margin %13.222.3 59.1%  
Effective tax rate %32.436.3 89.4%   
Net profit margin %-55.812.5 -445.0%  
BALANCE SHEET DATA
Current assets Rs m14,33515,673 91.5%   
Current liabilities Rs m49,8096,678 745.9%   
Net working cap to sales %-494.038.0 -1,300.9%  
Current ratio x0.32.3 12.3%  
Inventory Days Days40376 530.8%  
Debtors Days Days17122 764.8%  
Net fixed assets Rs m55,4328,098 684.5%   
Share capital Rs m268230 116.3%   
"Free" reserves Rs m13,93517,088 81.5%   
Net worth Rs m14,70117,356 84.7%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98825,400 291.3%  
Interest coverage x-0.4311.7 -0.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.10.9 10.4%   
Return on assets %0.511.8 4.3%  
Return on equity %-27.317.1 -159.3%  
Return on capital %-6.426.9 -23.9%  
Exports to sales %25.924.5 105.8%   
Imports to sales %0.228.0 0.6%   
Exports (fob) Rs m1,8605,801 32.1%   
Imports (cif) Rs m126,627 0.2%   
Fx inflow Rs m1,8607,145 26.0%   
Fx outflow Rs m256,846 0.4%   
Net fx Rs m1,835299 613.7%   
CASH FLOW
From Operations Rs m1,7193,226 53.3%  
From Investments Rs m-3,148-1,555 202.5%  
From Financial Activity Rs m1,426-1,818 -78.4%  
Net Cashflow Rs m-3-147 2.3%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.0 14.4 -  
FIIs % 9.9 14.6 67.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 10.5 374.3%  
Shareholders   21,482 15,184 141.5%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare STERLING BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Sep 24, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - MERCK LTD COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS